Table 1.
Clinicopathological data
| Non‐failing hearts (n = 20) | DCM (n = 75) | |||||
|---|---|---|---|---|---|---|
| Mean ± SD or n | Limits | Mean ± SD or n | Limits | Correlation with %5‐mC+ cardiomyocyte | ||
| r value | P value | |||||
| Clinical data | ||||||
| Age (year old) | 56 ± 17 | 14–77 | 58 ± 14 | 17‐81 | −0.0661 | 0.5730 |
| Gender (M/F) | 11/9 | — | 51/24 | — | — | — |
| LVSP (mm Hg) | 137 ± 29 | 100–200 | 135 ± 25 | 75–200 | −0.0314 | 0.7892 |
| LVEDP (mm Hg) | 13 ± 5.9 | 4–25 | 16 ± 8.2 | 4–40 | 0.2397 | 0.0397 |
| Heart rate (bpm) | 68 ± 13 | 47–94 | 77 ± 16* | 53–132 | 0.2391 | 0.0388 |
| LVEF (%) | 64 ± 6 | 55–76 | 38 ± 10* | 10–54 | −0.2917 | 0.0111 |
| LVEDVI (ml/m2) | 90 ± 19 | 57–135 | 124 ± 39* | 30–222 | 0.2442 | 0.0347 |
| LVESVI (ml/m2) | 32 ± 10 | 12–57 | 78 ± 33* | 15–169 | 0.3136 | 0.0062 |
| LVMI (g/m2) | 101 ± 42 | 57–206 | 137 ± 41* | 65–248 | 0.2287 | 0.0484 |
| Histological data | ||||||
| Cardiomyocyte size (μm) | 17 ± 2.6 | 12.8–21.8 | 26 ± 4.7* | 13.9–40.3 | 0.0248 | 0.8325 |
| Degree of fibrosis (0–3) | 1.0 ± 0.7 | 0–2 | 1.7 ± 0.7* | 0.5–3 | 0.0296 | 0.8009 |
| Inflammatory cells (per HPF) | 0.4 ± 0.5 | 0–1 | 0.9 ± 0.6* | 0–2 | 0.0513 | 0.6621 |
| Cardiomyocyte population (%)a | 33 ± 5.3 | 24–38 | 23 ± 3.6* | 18–28 | — | — |
LVSP and LVEDP, left ventricular peak systolic and end‐diastolic pressure; LVEDVI and LVESVI, left ventricular end‐diastolic and end‐systolic volume index; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; HPF, high power field.
*
P < 0.05 vs. non‐failing hearts.
a
n = 6 in each group.